By Purnendu Ghosh Dec 21 2009
The research conducted at the Israel (Novocure, Israel Institute of Technology, Weizmann Institute of Science and Elisha Medical Centre) indicate disruption of cancer cell replication by alternating electric fields. The effect is found to be selective, affecting only dividing cell lines and sparing the quiescent ones. The electric field arrests cell proliferation as well as destructi on of cells while undergoing division. Just before a dividing cell splits in two, it briefly forms an hourglass shape before the two daughter cells pinch off, and this shape is particularly vulnerable to electricity. The current gets concentrated at the cellâs narrow waist, and at the very moment of division, the cell membrane is destroyed, and the cells disintegrate. The mechanism of action of the fields, researchers say, depends on disruption of the microtubules of the mitotic spindle and the electric forces resulting from focusing of the field in the dividing cells. The spindle is composed of cell components known as microtubules. The microtubules contain components that have high electric dipole moment, in which there is a large separation of opposite electric charges. Therefore, parts of the mitotic spindle are greatly influenced and apparently get disrupted by an electric field.
The cancer fighting abilities of this technique are being evaluated on human p atients with recurrent glioblastoma multiforme (GBM); a fast growing, and difficult to treat form of brain cancer. This new technique exploits the difference between normal cells and cancer cells; it acts only on physically splitting cancer cells. The researchers are optimistic as they observed slower than usual progress in the development of brain tumour; in some cases even cell regression was observed. It is believed that this technique will work on all type of cancers and can possibly be applied to many different disease types. When the technique is applied in association with chemotherapy, its effect has been found more promising; the electric fields appear to make the cancer cells far more susceptible to chemotherapy without any additional increase in side effects and toxicity.
MarketWatch.com - Pre-Market Indications
Wednesday, January 13, 2010
Posted by st0ckman at 9:00 PM
NYSE Arca Morning Update for Wednesday, Jan 13, 2010 :
STOCKS TRADING ON NYSE Arca AT A PRICE 15% OR MORE AWAY FROM
THE PREVIOUS TRADE DAY'S CONSOLIDATED CLOSE PRICE (AS OF 08:30:00 ET)
Stock Tuesday's Close Current Price Pct Change Current NYSE ARCA Vol
BIDU $386.62 $448.15 15.9% 275,553
10 MOST ACTIVE STOCKS ON NYSE ARCA AS OF 08:30:00 ET
BASED ON DOLLARS TRADED: | BASED ON SHARES TRADED:
Stock $ Volume Price PctChg | Stock Share Vol Price PctChg
BIDU $122577857 $448.15 15.9% | C 10,876,133 $3.54 0.9%
SPY $48,028,222 $114.06 0.4% | MRNA 1,004,265 $1.64 72.4%
C $38,649,845 $3.54 0.9% | NEXM 629,690 $0.70 ( 5.6%)
GLD $23,936,967 $111.18 0.6% | SPY 421,110 $114.06 0.4%
IWM $20,733,370 $63.79 0.4% | BAC 360,768 $16.43 0.5%
GOOG $16,445,983 $581.00 ( 1.8%) | IWM 324,800 $63.79 0.4%
QQQQ $6,846,112 $45.97 0.4% | BIDU 275,553 $448.15 15.9%
BAC $5,932,310 $16.43 0.5% | YRCW 243,301 $1.14 4.0%
AAPL $3,166,724 $207.70 ( 0.0%) | GLD 215,289 $111.18 0.6%
AA $2,912,293 $15.70 1.2% | AA 185,130 $15.70 1.2%
Price changes may be affected by symbol splits and dividends.
Consolidated close price is the last print (excluding prints with trade
conditions) prior to 4PM ET.
This information is also updated on our web page every morning at 8:35ET:
This material is for informational purposes only.
NYSE Euronext and its affiliates ("NYSE Arca") are not soliciting any action based upon it.
This material is not to be construed as an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.
Any opinions expressed in this material are NYSE Arca opinions only.
NYSE Arca undertakes no obligation to update any of the information contained in this material in light of new information or future events.
THIS MATERIAL IS PROVIDED BY NYSE ARCA "AS IS" AND WITHOUT WARRANTIES EXPRESS OR IMPLIED.
NYSE ARCA DISCLAIMS ALL WARRANTIES INCLUDING THE IMPLIED WARRANTIES OF MERCHANTIBILITY, TITLE, AND FITNESS FOR A PARTICULAR PURPOSE AS TO THIS MATERIAL.
IN NO EVENT SHALL NYSE ARCA BE LIABLE FOR DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER (INCLUDING BUT NOT LIMITED TO, LOST PROFITS, TRADING LOSSES AND DAMAGES THAT MAY RESULT FROM THE USE
OF THIS MATERIAL, ANY DELAY OR INTERRUPTION OF SERVICE OR OMISSIONS OR INACCURACIES IN THE MATERIAL) WITH RESPECT TO THIS MATERIAL.
Copyright  by NYSE Euronext. All rights reserved. Reproduction and redistribution prohibited without prior express consent.
Posted by st0ckman at 8:31 AM